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ABSTRACT G-proteins transduce signals along diverse pathways, but the factors involved in pathway selection are largely
unknown. Here, we have studied the ability of Gaq to select between two effectors—mammalian inositide-speciﬁc phospho-
lipase Cb (PLCb) and phosphoinositide-3-kinase (PI3K)—in human embryonic kidney 293 cells. These studies were carried out
by measuring interactions between eCFP- and eYFP-tagged proteins using Forster resonance energy transfer in the basal state
and during stimulation. Instead of association of Gaq with effectors through diffusion and exchange, we found separate and
stable pools of Gaq-PLCb and Gaq-PI3K complexes existing throughout the stimulation cycle. These separate complexes
existed despite the ability of Gaq to simultaneously bind both effectors as determined by in vitro measurements using puriﬁed
proteins. Preformed G-protein/effector complexes will limit the number of pathways that a given signal will take, which may sim-
plify predictive models.
INTRODUCTION
G-protein-coupled receptors (GPCRs) are the largest family
of mammalian transmembrane receptors and are activated by
agonists ranging from light to hormones to neurotransmitters
(1). Binding of an agonist to its speciﬁc GPCR enables the
receptor to activate heterotrimeric (GaGbg) G-proteins by
catalyzing the exchange of GTP for GDP on the a-subunit.
In principle, G-proteins can receive signals from multiple
GPCRs and have the potential to activate multiple pathways.
However, most signals only result in activation of a single
pathway, and our understanding of the factor(s) causing this
selection is limited.
Here, we have studied the ability of the Gaq family het-
erotrimeric G-proteins to discriminate between two effector
pathways: mammalian inositide-speciﬁc phospholipase Cb
(PLCb) and phosphoinositide 3-kinase (PI3K). Gaq-subunits
are coupled to receptors that bind agonists such as cate-
cholamines, bradykinin, endothelin-1, prostaglandin F2, and
angiotensin II. Their main effector is PLCb, which catalyzes
the hydrolysis of the minor lipid phosphatidylinositol 4,5
bisphosphate (PIP2) to produce second messengers that lead
to activation of protein kinase C and an increase in intracel-
lular calcium (2,3). These events in turn result in proliferative
and mitogenic changes in the cell. Several types of PLCb are
found in all mammalian cell lines, and all are activated by
Gaq. Activation of PLCbs by Gaq involves a large increase
in afﬁnity between the two proteins and changes in the nature
of their association (4). There are four known PLCb enzymes
(PLCb1–2) that differ in their tissue distribution, and all are
strongly activated by Gaq.
It was recently shown that Gaq has another effector: PI3K.
Class I PI3K enzymes phosphorylate PI(4,5)P2 to produce
PI(3,4,5)P3, which plays a key role in intracellular vesicle
trafﬁcking including transport of glucose transporters to the
plasma membrane surface needed for glucose uptake (5–7).
Class I PI3K enzymes are heterodimers composed of a reg-
ulatory subunit, p85, and a catalytic subunit, p110 (8). There
are several subtypes of p85 and p110 but only the p85a/
p110a subtype is a Gaq effector. The high correlation be-
tween human cancers and mutations in p110a (9) has at-
tracted keen interest in this protein. All PI3K subtypes are
ubiquitously expressed and activated by receptor tyrosine
kinases (RTKs) in response to stimulation by growth factors
(e.g., insulin, epidermal growth factor, insulin growth factor
(IGF), etc.). Activation is thought to occur by recruitment of
the p85 subunit through binding of its two SH2 domains to
the phosphorylated tyrosine residue of the activated RTK.
This recruitment brings the entire PI3K in close proximity to
the membrane surface and its PI(4,5)P2 substrate. Membrane-
bound PI3K then phosphorylates PI(4,5)P2 to produce
PI(3,4,5)P3, which then activates a number of downstream
pathways that control cell growth and survival. Unlike
PLCb, where GTP-bound Gaq increases its activity several-
fold, binding of PI3K to Gaq results in inhibition (10–12).
In a previous study, we characterized the cellular locali-
zation and association of Gaq and PLCb1 in two different
cell lines: the rat pheochromocytoma (PC12) and human
embryonic kidney 293 (HEK293) cell lines (13). We found
that Gaq is localized almost entirely on the plasma mem-
brane, whereas PLCb1 had a signiﬁcant cytosolic population
and a large plasma membrane population. We also found that
the amount of Gaq expressed in these cell lines exceeded
PLCb1. Using Forster resonance energy transfer (FRET), we
found that Gaq and PLCb1 were associated on the plasma
membrane in the basal state of both cell types. Activation of
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Gaq did not increase the observed FRET and did not alter the
amount of PLCb1 in the cytosol, suggesting that the gener-
ation of activated Gaq does not drive movement of the cy-
tosolic PLCb1 population to the plasma membrane. It is
therefore possible that this excess Gaq is free to interact with
its effector (PI3K) when PI3K is driven from the cytosol to
the plasma membrane upon RTK activation.
The presence of two Gaq effectors provides an opportunity
to determine how Gaq may discriminate between different
effectors under different conditions in living cells. In this
study, we used FRET to monitor the localization and Gaq
association of PI3K in living cells under basal conditions and
stimulation of RTK, GPCR, or both. We found that, like
PLCb1, there is a stable plasma membrane population of
preassociated Gaq-PI3K that is distinct from Gaq-PLCb
complexes. Thus, direct competition between the two effec-
tors does not occur; instead, there are different G-protein
populations that are dedicated to the two effectors. Interest-
ingly, this population of Gaq-PI3K complexes does not
signiﬁcantly change upon stimulation of either RTKs or
GPCRs. We propose that Gaq-PI3K complexes function to
preserve the amount of PIP2 substrate available for PLCb and
keep PI3K localized to the plasma membrane and inhibited
until displacement of Gaq by activated RTKs.
MATERIALS AND METHODS
Recombinant proteins
Puriﬁcation of the p85a/p110a complex from baculovirus-infected Sf9 cells
was described previously (12). PLCb2 and Gaq were also puriﬁed from an
Sf9 expression system (4). eCFP-Gaq and the constitutively active eCFP-
Gaq(R183C) were a generous gift from Dr. Catherine Berlot (Geisinger
Clinic, Danville, Pennsylvania). The constructs were derived from Gaq-
GFP, as described previously (14). The eCFP construct was originally ob-
tained from Clontech (Mountain View, CA). The mouse p110a subunit of
PI3 kinase (a generous gift from Dr. Richard Lin, Stony Brook University,
Stony Brook, NewYork) was ampliﬁed from the p3XFLAG-CMV-10 vector
using polymerase chain reaction and the following primers: forward: CCG
GGTACCATGCCTCCACGACCA; reverse: CGCGGATCC TCAGTT
CAAAGCATGCTG. It was then inserted into the eYFP-C1 vector between
the Kpn1 and BamH1 sites. To create eCFP-p110a we inserted p110a ob-
tained from the previous construct into the eCFP-C1 vector.
Cell culture and transfection
HEK293 and A10 cells were cultured in Dulbecco modiﬁed Eagle medium
supplemented with 10% fetal bovine serum (FBS), 50 U/mL of penicillin,
and 50 mg/mL streptomycin sulfate at 37C in a 5% CO2 incubator. C6 cells
were cultured in Roswell Park Memorial Institute-1640 medium supple-
mented with 7.5% FBS, 50 U/mL of penicillin, and 50 mg/mL streptomycin
sulfate at 37C in a 5% CO2 incubator.
C6, A10, and HEK293 cells were transfected using Lipofectamine rea-
gent (Invitrogen, Carlsbad, CA) according to the manufacturer’s protocol.
Brieﬂy, cells were grown on 60-mm dishes for 24–48 h to achieve 80–90%
conﬂuence. At 1 h prior to transfection, the growth medium was replaced
with Opti-MEM (Invitrogen, Eugene, OR) I reduced serum medium. Then,
5–10mg of DNA diluted with 300mLOpti-MEM I was mixed with 20 mL of
Lipofectamine diluted with 300 mL Opti-MEM I and incubated at room
temperature for 30 min to form complexes. The DNA-Lipofectamine com-
plexes were added to the cells, and the cells were returned to the incubator
and kept at 37C for 8–14 h. The Opti-MEM I medium was changed to full-
growth medium, and the cells were allowed to recover for 8–14 h. Next, the
cells were divided and placed into separate 35-mm glass-bottom culture
dishes (MatTek, Ashland, MA) and imaged 48–72 h later. HEK293 cells
were also transfected using the calcium phosphate coprecipitation method
in which 5–10 mg of plasmid was mixed with 120 mM CaCl2 and HBS
buffer (21 mM HEPES, 123 mM NaCl, 5 mM KCl, and 0.9 mM Na2HPO4,
pH 7.1), incubated on ice for 10 min, and added to cells maintained in 60-mm
dishes. Subsequent steps were identical with the Lipofectamine transfection.
Fluorescence measurements and data analysis
Puriﬁed Gaq was stored in a solution containing GDP. To activate Gaq, the
protein was incubated for 1 h at 30C in buffer (50 mM HEPES (pH 7.2),
100 mM (NH4)2SO4, 150 mM MgSO4 and 1 mM EDTA) containing
100 mM GTPgS, followed by dialysis against the same buffer plus 20 mM
2-mercaptoethanol (15). To activate Ras with GTPgS, the protein was in-
cubated with 20 mM HEPES (pH 7.2), 200 mM (NH4)2SO4, 5 mM EDTA,
and 5 mMGTPgS for 1 h on ice. The reaction was stopped by adding 20 mM
MgSO4 and dialyzed against 20 mM HEPES, 160 mM KCl, 6 mg GDP, and
1 mM 2-mercaptoethanol for 30 min.
Prior to labeling with coumarin (7-(dimethylamino)coumarin-4-acetic
acid succinimidyl ester; Molecular Probes, Eugene, OR), Gaq was dialyzed
against 20 mM HEPES and 160 mMKCl at pH 7.2 and then at the pH raised
to 8.0 with the addition of a small amount of concentrated phosphate buffer
before labeling with a fourfold molar excess of coumarin. The reaction
mixture was incubated on ice for 1 h; the unreacted probe was then removed
by dialysis against buffer at 4C.
Fluorescence measurements were performed on a spectroﬂuorometer
(ISS, Urbana, IL) using 3-mm pathlength cuvettes. Buffer controls used
dialysis buffer (20 mM HEPES, 160 mM KCL, 1 mM DTT, pH 7.2).
Samples contained 80 mM of LUV (POPC/POPS/POPE at a 1:1:1 molar
ratio) to inhibit protein aggregation. Coumarin-labeled proteins were excited
at 340 nM and scanned from 380 to 580 nM. Protein association was de-
termined by the increase in coumarin ﬂuorescence caused by the addition of
the unlabeled PI3K at three different initial concentrations of Gaq(GTPgS).
Signals were corrected for dilution and compared to the change in ﬂuores-
cence caused by addition of buffer alone. The titration curves were analyzed
as a bimolecular association to obtain the apparent dissociation constant (Kd).
The values of Kd for the three initial Gaq concentrations (5, 25, and 50 nM)
were within error of each other verify protein-protein interaction.
Immunoﬂuorescence
For colocalization experiments, we ﬁrst transfected HEK293 cells with p85a
and eYFP-p110a. Transfected cells were grown in poly-D-lysine-coated,
glass-bottom culture dishes (MatTek) for 48 h. The cells were washed with
warm phosphate-buffered saline (PBS) and ﬁxed with 1 mL of 3.7% for-
maldehyde at room temperature for 15 min. The ﬁxing solution was re-
moved, and the cells were washed three times with PBS. The cells were
permeabilized 5 min with 1 mL of 0.2% Nonidet P-40 (Roche, Mannheim,
Germany) in PBS. After permeabilization, the cells were blocked in Tris-
buffered saline (TBS: 10 mM Tris, 150 mM NaCl, pH 7.2) containing 4%
goat serum for 1 h. Cells were incubated with the primary antibody (rabbit
anti-PLCb1; Santa Cruz Biochemicals, Santa Cruz, CA) at 1:500 dilution in
TBS containing 1% goat serum at room temperature for 1 h and then washed
three times with TBS for 3 min each. Cells were incubated with Alexa647-
conjugated antirabbit secondary antibody (Invitrogen, Eugene, OR) (1:500
dilution) in TBS containing 1% goat serum at room temperature for 1 h, and
then washed three times with TBS for 3 min each.
In vivo single cell FRET measurements
In vivo FRET experiments were performed using a confocal laser scanning
microscope (LSM 510 Meta/Confocor 2 system; Zeiss, Jena, Germany).
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Filter settings were as follows: 1), eCFP was excited by the 458 nm line of an
argon-ion laser, and emission was collected using a 475- to 525-nm bandpass
ﬁlter; 2), eYFP was excited by the 514 nm line of an argon-ion laser, and
emission was collected using a 560- to 615-nm bandpass ﬁlter; and 3), for
FRET experiments, the sample was excited by the 458 nm line of an argon-
ion laser, and emission was collected using a 560- to 615-nm bandpass ﬁlter.
Bleed-through from eCFP ﬂuorescence into the FRET channel and direct
excitation of eYFP by the 458 nm laser line values were estimated from cells
transfected with 5 mg of free eCFP or free eYFP plasmids and from cells
transfected with eCFP-Gaq and eYFP p110a alone and imaged under the
appropriate ﬁlter sets. The maximum FRET value was determined from
control cells transfected with a construct composed of eCFP and eYFP
sandwiched between a 12-aa peptide (13,16).
FRET values were determined as follows:
netFRET ¼ IFRET  a3 IYFP  b3 ICFP;
where a is the percentage of bleed-through of CFP through FRET ﬁlter set
and b is the percentage of direct excitation of YFP by 458 nm light. To
compare FRET values among cells with varying protein expression levels,
we normalized the net FRET values (normalized FRET or NFRET)
according to Xia et al. (17) as follows:
NFRET ¼ IFRET  a3 IYFP  b3 ICFPﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
IYFP3 ICFP
p :
Colocalization
Cells were imaged using the multitrack mode of the Zeiss confocal laser
scanning microscope system. EYFP was excited with a 514-nm laser line,
and emission was measured using the LP530 ﬁlter. Alexa 647 was excited
with a 633-nm line of an HeNe laser, and the emission spectrum was mea-
sured using the LP 650 ﬁlter. Filters were obtained from Zeiss; images were
analyzed using software from Zeiss.
RESULTS
Localization of Gaq and its effectors in the basal
and stimulated states in living cells
We have previously characterized the localization of PLCb1
and Gaq in PC12 and HEK293 cells (13). In both cell lines,
we found that Gaq is almost exclusively on the plasma
membrane in the basal and stimulated states, whereas PLCb1
has a signiﬁcant cytosolic population and a plasma mem-
brane population. The amount of PLCb1 in these two cellular
compartments did not change upon Gaq activation, showing
no net movement to or from the plasma membrane.
PI3K has been found to be localized mainly in the cytosol,
although a small plasma membrane fraction and a focal ad-
hesion population has been reported (18). In cells, PI3K has
been shown to exist as a tightly bound heterodimer consisting
of p110 and p85 subunits (8). To determine the localization of
PI3K in different cell lines, we overexpressed eYFP-p110a
concomitantly with p85a and monitored the localization in
the basal and stimulated states in HEK293, A10, and C6
cells. Because expression of the untagged p85a subunit
cannot be visualized, we veriﬁed its expression byWestern blot
analysis. We ﬁnd that, under our conditions, it is expressed at a
level approximately twofold higher than endogenous.
In accordance with previous studies, we found that the
overexpressed p85a/eYFP-p110a, which we will refer to as
eYFP-PI3K, is mainly cytosolic but also has a small popu-
lation localized on the plasma membrane (Fig. 1 A). Inter-
estingly, the distribution of the enzyme is very punctuate and
similar in appearance to images of some of its protein part-
ners (5), which suggests that PI3K is contained in large do-
mains or protein aggregates. An analysis of the intensity
distributions of the eYFPp110a ﬂuorescence coexpressed
with p85a along the z axis of the cell shows that the intensity
distribution is close to the plasma membranes in HEK293
cells (Fig. 1 C), whereas the intensity distribution is seen
internally in C6 glial cells (Fig. 1 D). These varying cell dis-
tributions are thought to reﬂect the dynamic nature of PI3K
localization and sharply contrast the more uniform localization
and even distributions seen for PLCb, Gaq, and GPCRs
(13,14,16).
Cell fractionation studies have suggested that PI3K moves
from the cytosol to the plasma membrane by activated RTK
to access its PIP2 substrate (19). Additionally, live cell imaging
studies that followed movement of GFP-p85a in NIH3T3,
A431, and MCG-7 cells have shown redistribution from the
cytosol to the plasma membrane upon epidermal growth
factor stimulation (18). We monitored p85a/eYFP-p110a
expressed in HEK293 and C6 cells upon stimulation with 100
ng/mL IGF-1 (Fig. 1 B). We observed translocation with stim-
ulation, showing that the overexpressed p85a and eYFPp110a
are complexed and allow for interactions with activated RTK.
We note that the punctuate distribution of PI3K makes it
difﬁcult to quantify the overall amount of translocation in the
various cell types by image analysis.
FRET studies show that PI3K and Gaq are
associated in unstimulated cells
To determine whether the plasma membrane population of
PI3K is complexed with Gaq in the basal state, we measured
the amount of FRET from eCFP-Gaq to eYFP-PI3K. In ac-
cordance with the cellular distribution of the proteins, we
found FRET in a punctuate distribution only on the plasma
membrane. Fig. 2 shows the raw images through the CFP (A),
YFP (B), and FRET (C) channels and the corresponding
NFRET image (see Materials and Methods) of a represen-
tative cell. The results of several studies are compiled in
Table 1. It is surprising that the average amount of FRET
between the two proteins is relatively high (in HEK293 cells,
the overall NFRET is 0.48 6 0.07) and on the order of the
amount seen for Gaq-PLCb1 complexes (13). This value can
be compared to those obtained for eCFP and eYFP attached
by a small peptide linker (80%) and free eCFP and eYFP
(10%). Interestingly, the distribution of FRET values be-
tween Gaq and PI3K and between Gaq and PLCb1 differs
greatly. In Fig. 3, we compare the distribution of FRET
values where we have normalized the sum of the values to
1.0. A majority of the FRET values for PI3K are very low,
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whereas the remainder is spread over higher values. In con-
trast, the distribution for Gaq-PLCb is narrower and suggests
more well-deﬁned complexes.
In previous studies using puriﬁed proteins, we found that
PI3K binds to activated Gaq with an afﬁnity at least 10-fold
stronger than the deactivated form (20). Based on these
studies, we expected an increased association between PI3K
and activated Gaq. To determine whether the level of FRET
changes with Gaq stimulation, we performed two types of
studies. In the ﬁrst series of experiments, we monitored the
FRET signal before and after stimulation with the Gaq-
coupled agonist carbachol. No signiﬁcant changes in the
magnitude and distribution of FRET were observed. In a
second series of experiments, we repeated FRET studies
using a constitutively active form of Gaq—Gaq R183C (21).
This construct lacked GTPase activity and thus remained in
the activated state. Again, no signiﬁcant differences in FRET
between this construct and the wild-type construct were ob-
served, suggesting that Gaq-PI3K association in living cells
is independent of the state of activation.
Stimulation of cells with RTK activators, such as IGF-1,
results in an increase in the membrane population of PI3K and
thus we expected an increase in the plasma membrane-bound
PI3K-Gaq complexes. However, the extent of FRET between
Gaq and PI3K remained constant upon stimulationwith 100 ng/
mL IGF-1. This result implies that the membrane binding sites
of PI3K are distinct from those where Gaq is localized and that
Gaq-PI3K complexes are stable through the activation cycle. To
determine whether activation of Gaq together with RTK acti-
vation changes the amount of complexation, we simultaneously
stimulated the cells with both IGF and carbachol. Again, the
values of FRET remained constant. Taken together, these results
strongly suggest that there is a constant pool of Gaq-PI3K that
remains complexed through various types of cell stimulation.
In vitro puriﬁed Gaq binds independently to
either PLCb2 or PI3K
The studies described above show that a population of Gaq is
stably complexed with PI3K; also, in previous work (13), we
showed that a population of Gaq is stably complexed with
PLCb1. It could be possible that Gaq is associated to both
effectors in cells in higher-order complexes.We ﬁrst tested this
idea in vitro using puriﬁed proteins. These studies were carried
FIGURE 1 Image of a representative HEK293 cell
expressing p85a/eYFP-p110a showing its cellular dis-
tribution after serum starvation for 24 h (A) and stim-
ulation with 100 ng/mL of IGF-1 for 15 min (B). (C and
D) Distribution of the eYFP-p110a intensity along a
33 3 pixel point along the z axis in a HEK293 cell and
a C6 glial cell where the error is the standard deviation
derived from the average of the nine pixels in the 33 3
sampling at each point (see Materials and Methods).
The integration time is 6.4 ms/pixel.
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out by labeling puriﬁed Gaq with the ﬂuorescence probe
coumarin, placing a small amount (1, 5, or 20 nM) of the ac-
tivated (i.e., GTPgS-bound) protein in a cuvette andmeasuring
the increase in afﬁnity when PI3K (p110a/p85a) binds (for
complete details see Ballou et al. (20)). This titration curve was
then repeated in presence of PLCb2 at a concentration ;2
orders of magnitude higher than its dissociation constant for
Gaq (80 nM). The results show that the presence of PLCb2 has
no measurable effect on the binding of PI3K to Gaq (Fig. 4),
which suggest that Gaq can bind both effectors simultaneously.
Separate pools of Gaq associate with
each effector
The observation that Gaq may be capable of binding both
effectors in vitro leads to the possibility that ternary com-
plexes may form in cells. However, based on the high amount
of FRET between Gaq and each effector that remains un-
changed in the basal and stimulated states, we propose that
cells contain separate pools of Gaq-PLCb and Gaq-PI3K
complexes. If this is the case, we predict that PI3K and PLCb
should exist in separate regions in the cell. We ﬁrst tested this
idea by measuring the amount of colocalization between
PI3K and PLCb by viewing expressed eYFP-PI3K ﬂuores-
cence in HEK293 cells and viewing endogenous PLCb by
immunostaining. Colocalization between the two effectors
was only seen in very sparse points at adhesion sites (Fig.
5 A), suggesting that colocalization may be due to crowding
rather than ternary PI3K-Gaq-PLCb complexes. We then
directly tested for ternary complexes by measuring the ability
of eCFP-PI3K to FRET with eYFP-PLCb in HEK293 cells.
The normalized FRET value (0.16 6 0.02; n ¼26) was sig-
niﬁcantly lower than the value obtained for eYFP-Gaq and
eCFP-p110a (0.48 6 0.07; n ¼115) and close to the value
FIGURE 2 eCFP-Gaq-p85a/eYFPp110a FRET in a
HEK293 cell. Image of a representative HEK293 cell as
viewed through the CFP ﬁler to image eCFP-Gaq (A), the
YFP ﬁler to image eYFP-PI3K (B), and the FRET ﬁlter (C).
The normalized FRET is shown in panel D (see Materials
and Methods for details).
TABLE 1 Summary of FRET results
Cell Type Proteins expressed Cell state FRET
HEK293 eYFP-p110a, eCFP-Gaq Basal 0.43 6 0.02, n ¼ 4
HEK293 eYFP-p110a, p85a, eCFP-Gaq Basal 0.49 6 0.01, n ¼ 7
HEK293 eYFP-p110a, p85a, eCFP-GaqRC Basal 0.33 6 0.06, n ¼ 4
HEK293 eYFP-p110a, p85a, eCFP-Gaq Basal and carbachol stimulated 0.45 6 0.01, n ¼ 5 basal
0.45 6 0.01, n ¼ 3 with carbachol
HEK293 eYFP-p110a, p85a, eCFP-Gaq Basal and IGF stimulated 0.40 6 0.04, n ¼ 5 basal
0.40 6 0.01, n ¼ 3 with IGF
C6 eYFP-p110a, p85a, eCFP-Gaq Basal 0.44 6 0.05, n ¼ 3
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measured for non-interacting proteins (0.10, see Methods).
Interestingly, we found FRET from a few pixels in the cell
images (Fig. 5 B), suggesting that the two enzymes are not in
close proximity; instead, their FRET is due to stochastic
diffusion on the plasma member or they interact by virtue of
being part of larger membrane protein aggregates.
DISCUSSION
Cells receive signals from their environment; these signals
have the potential to activate multiple pathways. Although
some pathways are parallel, others converge onto modules
that may allow for signals to be redirected depending on the
circumstances. Here, we have investigated the ability of a
signal transducer to select two complementary pathways: 1),
activation of PLCb to increase intracellular Ca21 signals
through PIP2 hydrolysis, and 2), inhibition of vesicle traf-
ﬁcking events through inhibition of phosphorylation of PIP2
by PI3K. We found that, instead of Gaq selecting a speciﬁc
effector during a stimulation event, separate pools of Gaq-
effector complexes exist, thus making the signaling process
less dynamic than expected. These separate pools keep sig-
nals along a particular pathway, reducing the likelihood of
cross talk. As argued below, we propose that, although Gaq
stimulation of PLCb represents a forward motion pathway to
stimulate cellular events, Gaq inhibition of PI3K serves as a
backward motion to suppress cellular events.
We ﬁrst characterized the cellular localization of PI3K
using a ﬂuorescent-tagged chimera. We found that, in direct
contrast to the plasma membrane localization of Gaq, PI3K
was widely distributed throughout the cytoplasm and plasma
membrane (Fig. 1). This distribution correlates well with the
function of PI3K and with previous imaging studies (18). It is
interesting to note that, unlike the even distributions of Gaq
and PLCb in cells, PI3K is punctuated in appearance. This
punctuate distribution of PI3K most likely reﬂects high
concentrations of the enzyme on internal vesicles correlating
to its role in endocytic trafﬁcking. The punctuate distribution
of PI3K on the plasma membrane is also seen for RTKs (5),
suggesting colocalization of these proteins.
We found a signiﬁcant amount of FRET between Gaq and
PI3K. The distance at which half of the donor ﬂuorescence is
lost to transfer (i.e., Ro) for the eCFP and eYFP pair is 30 A˚
(22). Control studies using noninteracting donor/acceptors on
the instrumentation used in this study showed the stochastic
FRET to be 10%. Although most of the values for Gaq-PI3K
are lower than this value, there is a broad range of high FRET
values that contrast sharply with the more narrow distribution
seen for Gaq-PLCb complexes (Fig. 3). We speculate that
this broad range of FRET values reﬂects the punctuate dis-
tribution of PI3K aggregates on the plasma membrane that
contain varying amounts of Gaq, possibly resulting from
inefﬁcient dissolution of internal vesicles containing PI3K as
seen in Fig. 2 D.
The key ﬁnding of this study is that separate pools of Gaq
exist for both effectors. PLCb has long been established as
the main effector of Gaq, but it was puzzling that the cellular
amount of PLCb was far less than Gaq (13), suggesting that
Gaq may interact with other cellular proteins. Recently, Lin
and colleagues have discovered another Gaq effector (PI3K)
that linked two distinct cell signaling pathways—GPCRs
and RTKs (10–12). Although the afﬁnity of activated Gaq is
approximately threefold stronger for PLCb than for PI3K
(20), the afﬁnities for deactivated Gaq are comparable, sug-
gesting that Gaq can be bound to either depending on their
local concentrations and presence of competing proteins.
Thus, Gaq will bind to whichever effector is available,
thereby directing the signal in either direction. We found that,
instead of Gaq transducing a signal through diffusion and
binding with effectors, there were at least two populations
of Gaq preassociated with each effector in the basal and
stimulated states. Whereas the advantage of preformed Gaq-
PLCb can be understood in terms of rapid signal transduc-
FIGURE 4 Binding of PI3K to 5 nM Gaq(GTPgS) in the absence and
presence of PLCb. In vitro ﬂuorescence binding assay showing the change
in the normalized ﬂuorescence intensity of 5 nM activated CM-Gaq as
puriﬁed PI3K is added, where the total increase in intensity was ;18%.
Experiments were performed in triplicate; the results are mean 6 SE.
FIGURE 3 Distributions of FRET values for Gaq and its effectors. Com-
parison of the distribution of the magnitude of the FRET values for eCFP-
Gaq-eYFP-PLCb (open squares) and eYFP-Gaq and p85a/eCFP-p110a
(solid circles) in HEK293 cells. The FRET values for each complex were
summed and normalized to 1.0. Standard deviation is shown.
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tion, the role of preassociated Gaq-PI3K complexes is not as
clear. We speculate that the function of the Gaq-PI3K asso-
ciation is to prevent PIP2 phosphorylation by the plasma
membrane pool of PI3K during GPCR activation, thus en-
suring that the PLCb substrate does not become depleted. In
this way, Gaq could serve as an indirect local regulator of the
PIP2 level on the plasma membrane.
Our in vitro studies suggest the possibility that Gaq can
bind both effectors simultaneously. We tested this idea by
determining the amount of colocalization of the two effectors
and the amount of FRET between their ﬂuorescent constructs
in cells. We found that PLCb and PI3K are only associated in
a few points in the cell. This result suggests that the two
signaling pathways are isolated, although it is possible that a
few complexes containing these proteins exist, thereby al-
lowing for cross talk between the pathways.
Although the delineation of signaling pathways is difﬁcult,
the ﬁnding that cells may have preselected pathways for
signals to follow may help to simplify predictive models. It
would be very interesting to determine whether other path-
ways are also preselected.
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